Navigation Links
APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine

Leading medical centers in North America participate in study to evaluate the safety and efficacy of cyclosporine inhalation solution in preventing chronic rejection in lung transplant recipients.

Burlingame, CA (PRWEB) February 24, 2010 -- APT Pharmaceuticals, a specialty drug development company focused on the development of inhaled cyclosporine, announced today that it has completed enrollment in its Phase III CYCLIST trial. The multi-center, randomized, controlled study enrolled 288 recent lung transplant recipients across 19 leading centers in North America, including the Cleveland Clinic; the University of Pittsburgh; and the University of California, San Francisco.

The objective of the CYCLIST trial is to evaluate the safety and efficacy of cyclosporine inhalation solution in improving bronchiolitis obliterans syndrome (BOS)-free survival following lung transplantation. Lung transplantation is a life-saving procedure for people with end-stage lung diseases who have exhausted all other available treatment options. However, average survival post-lung transplant is less than five years -- significantly less than all other forms of solid organ transplant. Poor long-term outcomes in lung transplant patients appear to relate to BOS, a manifestation of chronic rejection, which remains a persistent problem despite administration of multi-drug systemic immunosuppressive regimens.

"We appreciate the broad support provided by the community of lung transplant centers, advocacy groups, patients and caregivers," said Dr. Charlie Johnson, chief medical officer of APT Pharmaceuticals. "They have exceeded our expectations by enrolling this trial in just over a year."

About Cyclosporine Inhalation Solution

Cyclosporine Inhalation Solution (CIS) is an inhaled formulation of cyclosporine A, an oral medication that has been widely used for over 25 years to prevent rejection in solid organ transplant recipients. Preliminary clinical studies of CIS in lung transplant recipients have been conducted, including a placebo-controlled study that was published as the lead article in the New England Journal of Medicine in January 2006 (Iacono et al 2006). This small, single-center, randomized, controlled, Phase II study showed that administration of inhaled cyclosporine, initiated soon after transplantation, reduced chronic rejection and improved survival while not increasing the risk of infection. This study led to the multi-center, APT Phase III CYCLIST study.

About APT Pharmaceuticals, Inc.

APT Pharmaceuticals, Inc. is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. Leading life sciences investors Charter Life Sciences, Great Point Partners, InterWest Partners, Pinnacle Ventures, Research Corporation Technologies, Three Arch Partners, Versant Ventures and Vivo Ventures back APT.


Cyclosporine Inhalation Solution (CIS) is an investigational drug and is not currently approved by the FDA.

For more information about APT, please visit

For more information about the CYCLIST trial, please visit


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would like to ... Deloitte's 2015 Technology Fast 500 list of the fastest growing companies in North ... II medical device that speeds up orthodontic tooth movement by as much as ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
(Date:10/23/2015)... Oct. 23, 2015 Research and Markets ( ... "Global Voice Recognition Biometrics Market 2015-2019" report to ... --> The global voice recognition biometrics market to ... --> --> The ... prepared based on an in-depth market analysis with inputs ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):